Sinopharm

As countries scramble for COVID-19 jabs, Mongolia's vaccine stocks swell

Mongolia, using its status as a small geopolitical player between Russia and China, was able to purchase 5 million doses from both countries

From supply chains to vaccines, China has frequently thrown spanner into works of India's COVID-19 battle

From tactfully disallowing Chinese firms to participate in BMC's global vaccine tender to exorbitant pricing of necessary equipment, India's battle against COVID-19 has often run into rough weather with China

WHO approves China's Sinopharm COVID-19 vaccine for emergency use

Sinopharm is a two jab inactivated vaccine and its easy storage requirements make it highly suitable for low-resource settings, the WHO said in a statement

Imran Khan testing COVID-19 positive days after Sinopharm dose raises questions about efficacy of China's vaccine

Pakistan has launched its vaccination drive for the general public on 10 March, starting with elderly people after seeing a poor response from front-line health workers, who expressed concerns about the Chinese vaccine

Pfizer, Moderna, Astrazeneca, Bharat Biotech, other COVID-19 vaccines in use or getting close

The shots were all tested differently, and some were allowed to go into use even before they were rigorously tested.

Bahrain approves use of Chinese COVID-19 vaccine; Kuwait gives nod for emergency use of Pfizer vaccine

Bahrain said over 7,700 signed up to take part in a trial of the Sinopharm vaccine in the Kingdom, but offered few details on the results of the study

China prepares for rollout of domestic Covid-19 vaccines in trial, pursues international deals

Orders for experimental, domestic Covid-19 vaccines are coming in, even though health officials are yet to vouch for them.

Pfizer announces $1.95 billion deal to produce 100 million doses of coronavirus vaccine by year-end

Pfizer said that large-scale safety and efficacy trials were to begin this month, with a regulatory review set for as early as October, although nothing was guaranteed.

CanSino Biologics in talks with Russia, Brazil, Chile, Saudi Arabia to launch Phase III trial of its COVID-19 vaccine

Qiu Dongxu co-founder of CanSino said its new factory under construction in China will allow it to produce 100-200 million vaccine doses per year by early 2021.

COVID-19 vaccine: Potential coronavirus vaccine candidate from China shows promise in animal tests

More than 100 potential COVID-19 vaccines are in various stages of development around the world.